It's every investor's dream. And this one came true... For lucky shareholders in this formerly tiny maker of automated medicine dispenser machines, last November's election changed everything.

No, not that election. And, no, not just any medicine.

I'm referring to the state ballot in Massachusetts... along with a medical treatment that's still illegal in most parts of the United States.

You see, the "medicine" that's distributed from this company's dispensers is marijuana. And after the Bay State's citizens voted to make Massachusetts the 19th U.S. state to allow the use of cannabis for medicinal purposes, the mainstream media took note. (Adding to the storyline was the fact residents of Washington and Colorado on the same day voted to make recreational use of marijuana legal.)

One week after the elections, The Wall Street Journal's Marketwatch.com published an article entitled "How to invest in legalized marijuana."

Topping Marketwatch's short list of stocks "for regular investors looking to get in on the action... without having to actually grow or sell drugs" was Hollywood, Calif.-based Medbox Inc. (OTC: MDBX), whose patented machines use biometrics to verify patients and doses. Also, as the company's founder told Marketwatch, the machines could potentially be used in ordinary drugstores too.

Two days later, the $4 stock was trading at $200 a share, and the $45 million company was worth billions. Now that's a Hollywood feel-good story if there ever was one.

Welcome to the world of game-changing stocks.

In the case of Medbox, share prices quickly fell just as fast, but not as far. On Friday, Dec. 28, MDBX closed at $63, down from the high, but still up a whopping 2,400% from the company's debut on the over-the-counter (OTC) market.



StreetAuthority's guide to investing in aggressive growth stocks is Andy Obermueller, Chief Investment Strategist for Game-Changing Stocks.

In his most recent issue, Andy pointed out that the Medbox example is extreme but hardly isolated. Every year -- regardless of the market environment -- companies emerge seemingly out of nowhere to deliver eye-popping returns to early shareholders.

Andy admitted he didn't see this one coming (for more on Andy's Medbox "confession," see the interview below).

But the fact that the sudden burst in Medbox was triggered by a news article suggests that neither did anyone else.

With or without Medbox, however, there was money to be made in the game-changing universe in 2012.

Last February, for instance, Andy recommended Human Genome Sciences (Nasdaq: HGSI), which had developed the first new drug in 50 years to treat Lupus, a chronic inflammatory disease that can affect various systems of the body, especially the skin, joints, blood and kidneys. At the time, HGS was trading at $9.16 a share; less than five months later, British pharmaceutical giant GlaxoSmithKline (NYSE: GSK) bought the company for $14.25 a share -- a 55.6% gain.

In July 2011 Andy named Celsion (Nasdaq: CLSN) his top cancer-treatment pick on the strength of a promising liver drug. At the time, the oncology drug developer was a $50 million company trading at $3.13 a share. Earlier this month, the $272 million company posted a 52-week high of $8.86 a share. That's a gain of $183% against a meager 6.8% increase in the S&P 500 during the same period.

This past summer, Andy published a special issue on business development companies (BDCs), which are a form of publicly traded private equity that invest in promising businesses. His top pick on June 20 from 27 such stock: Main Street Capital (Nasdaq: MAIN), which has since appreciated 26.5%.

For more on Andy's quest for game changers, read on...
________________________________________

Bob: What's your analysis of Medbox? At what price would you be a buyer?

Andy: Medbox is an important story for investors to be aware of. I hope that the huge returns catch people's attention. But let me be clear: I would not be a buyer of Medbox at anything near its current valuation. The stock flew too high, too fast. It is unlikely to be able to produce results that will justify its current prices.

But there is nevertheless a lot to learn from the phenomenon, a lot to take away from the idea that a stock can skyrocket because of an external catalyst.

First, a confession. I didn't conceive of the marijuana initiatives as an investment opportunity. So that has to be the first lesson: Never let a failure of imagination limit your investment choices. Do not confine your cerebral activity to the interior of an enclosed rectangular space. Or, to put it another way, "Think outside the box." I didn't on this one. I wish I had.

But having said that, let's look at Medbox. It's not actually in the marijuana business. It doesn't even make money from the sale of medicine. It simply provides machines that verify documentation and identity and then dispense. Now, as I mentioned in the newsletter, there's a lot of detail work in that -- tons of red tape to wade through. Medbox came up with a nifty tool to do just that. But CareFusion -- a stock I have recommended in the past -- has the same sort of dispensary, and with a much stronger brand and vastly superior market position. The Medbox technology is good, but it's not the only competitor in its field, nor is it the best. That's lesson two, then: Always invest in stocks with the best technology coupled with the best industry position.

Finally, and maybe more importantly, heed the words of country music legend Kenny Rogers, who tells us to "know when to walk away, and know when to run." Investors have to be clear-eyed as to whether a trend has played out. This one has. It played out on Election Day. MedBox was long on ink and light on squid. There is perspective to be gained, but that's the extent to which I would seek to profit from these shares at this point.

Bob: Some of the stocks I mentioned above, including Medbox, achieved game-changing status relatively quickly. But that's not always the case, is it?

Andy: Let me bring your attention to Obermueller's rule number two when it comes to investing in potential game changers: The aggressive growth investor must be patient. Or, to put it another way, "A nut has to stand his ground for a long time to become an oak."

If you look at companies that built and kept strong businesses, the stock chart is revealing. Typically, not all the years were good ones, and most success stories took years to make the journey from nano cap to mega cap.

In the most recent issue of Game-Changing Stocks, I cite the example of Apple (Nasdaq: AAPL). The iPod, the device that began Apple's transformative march, was released in November 2001. The share price was around twenty bucks at that time, and the stock was functionally dead money for two years. Thereafter, the shares rallied, though the company also saw periods where the stock turned negative.



That's why I frame my advice about patience in terms of its cousin, confidence. When you really understand why a stock is a real game changer, then you have confidence. Confidence must be present for patience to triumph.

Bob: What are some of your other rules for investing in game-changers?

Andy: The first rule is: Be realistic to the point of hyper rationality. There's a lot to know before investing, and that reality -- those realties -- have to be acknowledged and accepted for what they are. Being realistic means collecting and assimilating a lot of information. I know that might sound obvious, even silly, but I see people skip this every day. I get 100 emails a month from otherwise intelligent people who fail to heed the most basic information about their investments.

My third rule is a portfolio manager's most important job: allocation, allocation, allocation. Investors have to find a mix of securities that meets their needs and fits their risk profile. Aggressive growth should never make up more than 20% of a portfolio, and that might be high for some investors.

Bob: What are you looking at these days?

Andy: Health care, energy and some pure science - the next "big thing" stuff. I'm also interested in taking a global view of growth this year and investigating where the next boom will hit (my initial guess is Mongolia, though two other countries also intrigue me) I also see a whole lot of tech companies with a whole lot of cash on hand, and I'm interested to see what the early acquisitions in 2013 will foretell. So I'm all over the map. Basically, I hit the reset button every year and begin a new search. It might sound a bit chaotic, but I see a lot of areas to be really hopeful and excited about. I looked at the performance of the first year of second terms, and the average market gain since 1965 (Nixon 1973, Reagan 1985, Clinton 1997 and Bush 2005) was 13.8%, versus a historical average total S&P return of 10.9%. What's more, in two of those four years, the total return exceeded 30%. Given the relatively low earnings multiple of the market, 2013 might well be another breakout year.

[Note: As Andy is fond of saying, "all it takes is one solid game changer to move the needle on an entire portfolio." And Andy's had a number of them recently, including a pharmaceutical company that surged 55% in the five months following his recommendation... a biotech stock that is already up 183%... and a business development company that has gained 27% since he brought it to his subscribers' attention a few months ago.

To get Andy's latest pick, or to learn more about Game-Changing Stocks, you can follow this link here.]

Related Articles
  1. Personal Finance

    A Day in the Life of an Equity Research Analyst

    What does an equity research analyst do on an everyday basis?
  2. Mutual Funds & ETFs

    ETF Analysis: PowerShares S&P 500 Downside Hedged

    Find out about the PowerShares S&P 500 Downside Hedged ETF, and learn detailed information about characteristics, suitability and recommendations of it.
  3. Mutual Funds & ETFs

    ETF Analysis: ProShares Large Cap Core Plus

    Learn information about the ProShares Large Cap Core Plus ETF, and explore detailed analysis of its characteristics, suitability and recommendations.
  4. Mutual Funds & ETFs

    ETF Analysis: iShares Core Growth Allocation

    Find out about the iShares Core Growth Allocation Fund, and learn detailed information about its characteristics, suitability and recommendations.
  5. Mutual Funds & ETFs

    ETF Analysis: iShares MSCI USA Minimum Volatility

    Learn about the iShares MSCI USA Minimum Volatility exchange-traded fund, which invests in low-volatility equities traded on the U.S. stock market.
  6. Stock Analysis

    Should You Follow Millionaires into This Sector?

    Millionaire investors—and those who follow them—should take another look at the current economic situation before making any more investment decisions.
  7. Professionals

    What to do During a Market Correction

    The market has corrected...now what? Here's what you should consider rather than panicking.
  8. Mutual Funds & ETFs

    ETF Analysis: Vanguard Mid-Cap Value

    Take an in-depth look at the Vanguard Mid-Cap Value ETF, one of the largest and most popular mid-cap funds in the U.S. equity space.
  9. Mutual Funds & ETFs

    ETF Analysis: Schwab US Broad Market

    Take an in-depth look at the Schwab U.S. Broad Market ETF, an incredibly low-cost fund based on a wide selection of the U.S. equity market.
  10. Professionals

    Tips for Helping Clients Though Market Corrections

    When the stock market sees a steep drop, clients are bound to get anxious. Here are some tips for talking them off the ledge.
RELATED TERMS
  1. Equity

    The value of an asset less the value of all liabilities on that ...
  2. Fractal Markets Hypothesis (FMH)

    An alternative investment theory to Efficient Market Hypothesis ...
  3. Hard-To-Sell Asset

    An asset that is extremely difficult to dispose of either due ...
  4. Sucker Yield

    When an investor has essentially risked all of his capital for ...
  5. PT (Perseroan Terbatas)

    An acronym for Perseroan Terbatas, which is Limited Liability ...
  6. Ltd. (Limited)

    An abbreviation of "limited," Ltd. is a suffix that ...
RELATED FAQS
  1. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  2. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  3. How does additional paid in capital affect retained earnings?

    Both additional paid-in capital and retained earnings are entries under the shareholders' equity section of a company's balance ... Read Full Answer >>
  4. What types of capital are not considered share capital?

    The money a business uses to fund operations or growth is called capital, and there are a number of capital sources available. ... Read Full Answer >>
  5. What is the difference between issued share capital and subscribed share capital?

    The difference between subscribed share capital and issued share capital is the former relates to the amount of stock for ... Read Full Answer >>
  6. What happens to the shares of stock purchased in a tender offer?

    The shares of stock purchased in a tender offer become the property of the purchaser. From that point forward, the purchaser, ... Read Full Answer >>

You May Also Like

COMPANIES IN THIS ARTICLE
Trading Center
×

You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!